-1.png?width=1169&height=277&name=Inovia%20Logo%20Dark%20(1)-1.png)
Why the linear Big Pharma development model fails early-stage biotechs, and the agile, evidence-driven playbook that should replace it.
The evidence questions that come up in every diligence process, and how prepared companies answer them.
A case study on building a target product profile from evidence instead of guesswork, integrating indication selection and fast cross-functional input.
A playbook for standing up the function before you can afford the department.
How a first-time biotech shifts from clinical development to launch readiness, with medical affairs leading real-world evidence generation.
What evidence actually needs to cost pre-Series B, line by line.
